Mars JC, Culjkovic-Kraljacic B, Borden KLB. eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production. Nucleus. 2024;15(1):2360196.

Article  PubMed  PubMed Central  Google Scholar 

Yang X, Zhong W, Cao R. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer. Cell Signal. 2020;73:109689.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006;25(48):6416–22.

Article  CAS  PubMed  Google Scholar 

Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shveygert M, Kaiser C, Bradrick SS, Gromeier M. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol Cell Biol. 2010;30(21):5160–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter JH, Deddens JA, Spaulding NI, Lucas D, Colligan BM, Lewis TG, et al. Phosphorylation of eIF4E Serine 209 is associated with tumour progression and reduced survival in malignant melanoma. Br J Cancer. 2016;114(4):444–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther. 2009;8(15):1463–9.

Article  PubMed  Google Scholar 

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010;16(1):240–8.

Article  CAS  PubMed  Google Scholar 

Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 2015;34(16):2032–42.

Article  CAS  PubMed  Google Scholar 

Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A. 2010;107(32):14134–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;25(2):301–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, et al. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. J Clin Invest. 2021;131(8).

Guo Q, Bartish M, Goncalves C, Huang F, Smith-Voudouris J, Krisna SS, et al. The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer. Cancer Res. 2021;81(14):3876–89.

Article  CAS  PubMed  Google Scholar 

Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology State-of-the-Art review. JACC: CardioOncology. 2022;4(5):579–97.

PubMed  PubMed Central  Google Scholar 

Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535–e.

Article  PubMed  PubMed Central  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Reviews Clin Oncol. 2019;16(9):563–80.

Article  CAS  Google Scholar 

Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, et al. Immune-Related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open. 2024;7(1):e2352302–e.

Article  PubMed  PubMed Central  Google Scholar 

Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, et al. Immune checkpoint Inhibitor-Associated colitis: from mechanism to management. Front Immunol. 2021;12:800879.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced colitis. Am J Gastroenterol. 2020;115(2):202–10.

Article  PubMed  Google Scholar 

Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective. eClinicalMedicine. 2024;70.

Zoghbi M, Burk KJ, Haroun E, Saade M, Carreras MTC. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Support Care Cancer. 2024;32(10):680.

PubMed  PubMed Central  Google Scholar 

Varma S, Sullivan K, DiCarlo J, Coromilas A, Staller K, Dougan M. The development of persistent Gastrointestinal symptoms in patients with melanoma who have had an immune checkpoint Inhibitor-Related Gastrointestinal toxicity. Clin Transl Gastroenterol. 2024;15(8):e00746.

Article  PubMed  PubMed Central  Google Scholar 

Cappello G, Molea F, Campanella D, Galioto F, Russo F, Regge D. Gastrointestinal adverse events of immunotherapy. BJR Open. 2021;3(1):20210027.

PubMed  PubMed Central  Google Scholar 

Tomivosertib (eFT-508) in combination with PD-1/PD-L1 inhibitor therapy: a study of subjects administered anti-PD-1/anti-PD-L1 therapy that are experiencing insufficient response to checkpoint inhibitor alone [Internet]. Study registered on 2018/07/25 and completed on 2021-06-30. Available from: https://clinicaltrials.gov/study/NCT03616834

Ferrario C, Mackey J, Gelmon KA, Levasseur N, Sorensen PH, Oo HZ, et al. Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with Paclitaxel in patients with refractory metastatic breast cancer. Clin Cancer Res. 2025;31(3):491–502.

Article  CAS  PubMed  Google Scholar 

Gorentla BK, Krishna S, Shin J, Inoue M, Shinohara ML, Grayson JM, et al. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2013;190(3):1026–37.

Article  CAS  PubMed  Google Scholar 

Kim TW, Seo JN, Suh YH, Park HJ, Kim JH, Kim JY, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol. 2006;12(2):302–5.

Article  PubMed  PubMed Central  Google Scholar 

Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014;104:15.25.1-15.25.14.

Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–710.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85.

Article  CAS  PubMed  Google Scholar 

Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SEJ, Huang F, et al. Tunable phenocycler imaging of the murine pre-clinical tumour microenvironments. Cell Bioscience. 2024;14(1):19.

Article